Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast Cancer

The purpose of this study is to evaluate the efficacy and the safety of paclitaxel given weekly in patients with advanced or recurrent breast cancer

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Breast Cancer Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

20 year–74 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with primary advanced inoperable disease who were refractory to chemotherapy
Patients with recurrent disease following post-operative adjuvant chemotherapy
Patients who were not amenable to post-recurrence chemotherapy

Exclusion criteria

Patients with serious, uncontrolled medical illness
Patients with previous therapy with taxanes

Treatment and study plan

paclitaxel

Drug

Solution, IV, 100 mg/m², weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent

Other names: Taxol, BMS-181339

Primary outcomes

Response rate [defined as total number of patients with complete and partial response divided by number of response-evaluable patients] based on predetermined evaluation criteria

Time frame: Each 49 day course of treatment until withdrawal or unacceptable toxicity
Safety: incidence and severity of adverse events, laboratory test abnormalities

Time frame: Each 49 day course of treatment until withdrawal or unacceptable toxicity

Secondary outcomes

Duration of response, defined as either Complete or Partial Response, based on Evaluation Criteria on Therapeutic Effects in Patients with Advanced or Recurrent Breast Cancer

Time frame: Each 49 day course of treatment until withdrawal or unacceptable toxicity

Sponsors and collaborators

Lead sponsor

Bristol-Myers Squibb

Industry

Registry information

Important dates

Study start: 2002
Primary completion: 2005
Study completion: 2005
First posted: Dec 2, 2009
Registry last updated: Feb 4, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed